See more : MDxHealth SA (MDXH) Income Statement Analysis – Financial Results
Complete financial analysis of Enanta Pharmaceuticals, Inc. (ENTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enanta Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Multipolar Tbk (MLPL.JK) Income Statement Analysis – Financial Results
- PT Pratama Widya Tbk (PTPW.JK) Income Statement Analysis – Financial Results
- Juniper Networks, Inc. (JNP.DE) Income Statement Analysis – Financial Results
- Krypton Industries Limited (KRYPTONQ.BO) Income Statement Analysis – Financial Results
- Arista Power, Inc. (ASPW) Income Statement Analysis – Financial Results
Enanta Pharmaceuticals, Inc. (ENTA)
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67.64M | 79.20M | 86.16M | 97.07M | 122.47M | 205.20M | 206.63M | 102.81M | 88.27M | 160.88M | 47.74M | 32.05M | 41.71M | 41.88M | 22.76M |
| Cost of Revenue | 0.00 | 0.00 | 2.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 67.64M | 79.20M | 83.19M | 97.07M | 122.47M | 205.20M | 206.63M | 102.81M | 88.27M | 160.88M | 47.74M | 32.05M | 41.71M | 41.88M | 22.76M |
| Gross Profit Ratio | 100.00% | 100.00% | 96.55% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 131.48M | 163.52M | 164.52M | 174.11M | 136.76M | 142.21M | 94.86M | 57.45M | 40.46M | 23.19M | 18.74M | 16.84M | 15.12M | 11.55M | 9.72M |
| General & Administrative | 57.85M | 52.89M | 45.48M | 32.54M | 27.36M | 26.25M | 23.44M | 20.75M | 16.97M | 13.54M | 10.02M | 6.18M | 5.30M | 0.00 | 6.11M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 57.85M | 52.89M | 45.48M | 32.54M | 27.36M | 26.25M | 23.44M | 20.75M | 16.97M | 13.54M | 10.02M | 6.18M | 5.30M | 5.04M | 6.11M |
| Other Expenses | 0.00 | 0.00 | 83.00K | 1.99M | 6.62M | 8.82M | 4.79M | 2.33M | 1.72M | 1.31M | 283.00K | 598.00K | 0.00 | 5.04M | 309.00K |
| Operating Expenses | 189.33M | 216.41M | 210.00M | 206.65M | 164.11M | 168.46M | 118.30M | 78.20M | 57.43M | 36.73M | 28.76M | 23.02M | 20.42M | 16.58M | 15.82M |
| Cost & Expenses | 189.33M | 216.41M | 210.00M | 206.65M | 164.11M | 168.46M | 118.30M | 78.20M | 57.43M | 36.73M | 28.76M | 23.02M | 20.42M | 16.58M | 15.82M |
| Interest Income | 14.77M | 11.36M | 1.57M | 2.02M | 6.47M | 8.82M | 0.00 | 2.53M | 1.74M | 968.00K | 467.00K | 248.00K | 118.00K | 83.00K | 14.00K |
| Interest Expense | 10.94M | 5.15M | 1.57M | 0.00 | 0.00 | 8.82M | 4.85M | 40.00K | 45.00K | 8.00K | 18.00K | 31.00K | 0.00 | 3.16M | 0.00 |
| Depreciation & Amortization | 2.34M | 2.37M | 2.97M | 3.33M | 3.64M | 3.26M | 2.52M | 2.14M | 1.66M | 639.00K | 352.00K | 221.00K | 172.00K | 499.00K | 553.00K |
| EBITDA | -104.51M | -123.48M | -119.22M | -104.25M | -38.00M | 40.00M | 90.85M | 26.75M | 32.50M | 124.79M | 19.34M | 9.25M | 21.57M | 26.97M | 8.30M |
| EBITDA Ratio | -154.52% | -155.90% | -140.38% | -112.88% | -34.00% | 17.90% | 42.75% | 23.94% | 34.94% | 77.17% | 39.77% | 28.17% | 51.74% | 61.80% | 34.35% |
| Operating Income | -121.69M | -137.21M | -123.84M | -109.57M | -41.64M | 36.74M | 88.33M | 24.61M | 30.84M | 124.15M | 18.99M | 9.03M | 21.29M | 25.30M | 6.94M |
| Operating Income Ratio | -179.92% | -173.23% | -143.74% | -112.88% | -34.00% | 17.90% | 42.75% | 23.94% | 34.94% | 77.17% | 39.77% | 28.17% | 51.05% | 60.41% | 30.50% |
| Total Other Income/Expenses | 3.90M | 6.21M | 1.66M | 1.99M | 6.62M | 8.82M | 4.79M | 2.33M | 1.72M | 1.31M | 283.00K | 598.00K | 110.00K | -1.99M | 805.00K |
| Income Before Tax | -117.79M | -131.00M | -122.19M | -107.58M | -35.02M | 45.56M | 93.12M | 26.95M | 32.56M | 125.46M | 19.27M | 9.63M | 21.40M | 23.31M | 7.75M |
| Income Before Tax Ratio | -174.15% | -165.39% | -141.82% | -110.82% | -28.59% | 22.20% | 45.07% | 26.21% | 36.89% | 77.98% | 40.36% | 30.03% | 51.31% | 55.66% | 34.03% |
| Income Tax Expense | -1.74M | 2.82M | -433.00K | -28.58M | 1.15M | -826.00K | 21.17M | 9.24M | 10.89M | 46.46M | -15.17M | -221.00K | 0.00 | 3.16M | -157.00K |
| Net Income | -116.05M | -133.82M | -121.76M | -79.00M | -36.17M | 46.38M | 71.96M | 17.71M | 21.67M | 78.99M | 34.44M | 9.63M | 21.40M | 23.31M | 7.90M |
| Net Income Ratio | -171.58% | -168.95% | -141.31% | -81.38% | -29.53% | 22.60% | 34.82% | 17.23% | 24.55% | 49.10% | 72.14% | 30.03% | 51.31% | 55.66% | 34.72% |
| EPS | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.37 | 3.48 | 0.93 | 1.14 | 4.23 | 1.88 | -0.67 | 1.18 | 1.35 | 0.02 |
| EPS Diluted | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.21 | 3.48 | 0.91 | 1.13 | 4.09 | 1.80 | -0.67 | 0.52 | 0.59 | 0.02 |
| Weighted Avg Shares Out | 21.16M | 20.97M | 20.60M | 20.17M | 19.94M | 19.58M | 20.65M | 19.07M | 18.93M | 18.67M | 18.36M | 9.79M | 1.16M | 1.16M | 12.75M |
| Weighted Avg Shares Out (Dil) | 21.16M | 20.97M | 20.60M | 20.17M | 19.94M | 20.97M | 20.65M | 19.41M | 19.22M | 19.30M | 19.19M | 9.79M | 2.64M | 2.64M | 14.13M |
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023. “Throughout...
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal fourth quarter and full year ended September...
Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced it will host a virtual key opinion leader event to discuss advances in the treatment landscape for...
Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial...
Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-938, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial...
Enanta Pharmaceuticals to Participate in Investor Conferences in September
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that members of management will participate in four investor conferences being webcast in September and provide a business...
Why Shares of Enanta Pharmaceuticals Are Dropping Tuesday
The clinical-stage biotech receives most of its revenue from a royalty agreement with AbbVie. Enanta has a pipeline with eight programs.
Enanta Pharmaceuticals, Inc. (ENTA) Q3 2023 Earnings Call Transcript
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q3 2023 Results Conference Call August 7, 2023 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Officer Paul Mellett - Chief Financial Officer Tara Kieffer -...
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.86 per share versus the Zacks Consensus Estimate of a loss of $2.38. This compares to loss of $1.53 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports